MLLT3 and acute myeloid leukemia: Thus, these discovered circuits should offer additional therapeutic opportunities, both in the “reading” domains (YEATS of AF9 or ENL; PWWP of LEDGF) and the catalytic “writing” domains (SET of ASH1L and NSD1/3), for AML treatment.